Journal of Pathology and Translational Medicine

So Young Im

1 Article

Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer: Hong Sik Park, Uiju Cho, So Young Im, Chang Young Yoo, Ji Han Jung, Young Jin Suh, Hyun Joo Choi; J Pathol Transl Med. 2019;53(2):75-85. Published online November 14, 2018; DOI: https://doi.org/10.4132/jptm.2018.10.11

5,276 View
172 Download
20 Citations

Background
Human leukocyte antigen class I (HLA-I) molecules play important roles in regulating immune responses. Loss or reduction of HLA-I expression has been shown to be associated with prognosis in several cancers. Regulatory T-cells (Tregs) also play critical functions in immune response regulation. Evaluation of HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast cancer have not been well studied, and its relationship with Tregs remains unclear.
Methods
We evaluated HLA-I expression and Treg infiltration by immunohistochemistry in 465 surgically resected breast cancer samples. We examined the correlation between HLA-I expression and Treg infiltration and clinicopathologic characteristics and survival analyses were performed.
Results
Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). Univariate survival analysis revealed that loss of HLA-I expression was significantly associated with worse disease-specific survival (DSS) (p = .029). HLA-I was not an independent prognostic factor in the entire patient group, but it was an adverse independent prognostic factor for DSS in patients with advanced disease (stage II–IV) (p = .031). Treg numbers were significantly higher in the intratumoral stroma of HLA-I–positive tumors than in HLA-I–negative tumors (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). However, Tregs were not an independent prognostic factor in our cohort.
Conclusions
Our findings suggest that the loss of HLA-I expression is associated with poor prognosis in breast cancer patients, highlighting the role of HLA-I alterations in immune evasion mechanisms of breast cancer. HLA-I could be a promising marker that enables the application of more effective and precise immunotherapies for patients with advanced breast cancer.

Citations

Citations to this article as recorded by

HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
Ning Jiang, Yue Yu, Dawei Wu, Shuhang Wang, Yuan Fang, Huilei Miao, Peiwen Ma, Huiyao Huang, Min Zhang, Yu Zhang, Yu Tang, Ning Li
Journal of Cancer Research and Clinical Oncology.2023; 149(2): 737. CrossRef
Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance
Sonya Youngju Park, Deog-Gon Cho, Byoung-Yong Shim, Uiju Cho
Diagnostics.2023; 13(6): 1013. CrossRef
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors
Ananthan Sadagopan, Theodoros Michelakos, Gabriella Boyiadzis, Cristina Ferrone, Soldano Ferrone
JAMA Oncology.2022; 8(3): 462. CrossRef
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Brandie C. Taylor, Justin M. Balko
Frontiers in Immunology.2022;[Epub] CrossRef
Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives
Ioannis A. Vathiotis, Ioannis Trontzas, Niki Gavrielatou, Georgia Gomatou, Nikolaos K. Syrigos, Elias A. Kotteas
Clinical Breast Cancer.2022; 22(7): 642. CrossRef
Cancer Immunology: Immune Escape of Tumors—Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies
Yuan Wang, Simon Jasinski-Bergner, Claudia Wickenhauser, Barbara Seliger
Advances in Anatomic Pathology.2022;[Epub] CrossRef
Aberrant synaptophysin expression in classic Hodgkin lymphoma
Soyoung Im, Jeong-A. Kim, Gyeongsin Park, Uiju Cho
Diagnostic Pathology.2022;[Epub] CrossRef
Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer
Song-Hee Han, Milim Kim, Yul Ri Chung, Ji Won Woo, Hye Yeon Choi, So Yeon Park
Scientific Reports.2022;[Epub] CrossRef
In Silico Pipeline to Identify Tumor-Specific Antigens for Cancer Immunotherapy Using Exome Sequencing Data
Diego Morazán-Fernández, Javier Mora, Jose Arturo Molina-Mora
Phenomics.2022;[Epub] CrossRef
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng, Dong-Ming Kuang
Cellular and Molecular Life Sciences.2021; 78(3): 867. CrossRef
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara
Journal for ImmunoTherapy of Cancer.2021; 9(8): e002597. CrossRef
Resistance mechanisms to checkpoint inhibitors
Sarah A Weiss, Mario Sznol
Current Opinion in Immunology.2021; 69: 47. CrossRef
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Frontiers in Immunology.2021;[Epub] CrossRef
B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein
Pu Yu, Lili Zhu, Kang Cui, Yabing Du, Chaojie Zhang, Wang Ma, Jia Guo
Frontiers in Oncology.2021;[Epub] CrossRef
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltr
npj Breast Cancer.2021;[Epub] CrossRef
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Liam Masterson, James Howard, Jazmina Gonzalez‐Cruz, Christopher Jackson, Catherine Barnett, Lewis Overton, Howard Liu, Rahul Ladwa, Fiona Simpson, Margie McGrath, Ben Wallwork, Terry Jones, Christian Ottensmeier, Melvin L.K. Chua, Chris Perry, Rajiv Khan
International Journal of Cancer.2020; 146(8): 2305. CrossRef
Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi, Gary M. Tse
Cancer Immunology, Immunotherapy.2020; 69(5): 799. CrossRef
Breast cancer patients overall survival depends on a combination of the polymorphisms of tumor necrosis factor gene and HLA-haplotypes
T.F. Malivanova, E.V. Alferova, A.S. Ostashkin, T.A. Astrelina, N.N. Mazurenko
Molecular Genetics Microbiology and Virology (Russian version).2020; 38(1): 40. CrossRef
The Overall Survival of Breast Cancer Patients Depends on a Combination of Polymorphisms of Tumor Necrosis Factor Gene and HLA Haplotypes
T. F. Malivanova, E. V. Alferova, A. S. Ostashkin, T. A. Astrelina, N. N. Mazurenko
Molecular Genetics, Microbiology and Virology.2020; 35(1): 38. CrossRef
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Fernando Souza-Fonseca-Guimaraes, Joseph Cursons, Nicholas D. Huntington
Trends in Immunology.2019; 40(2): 142. CrossRef

Author index